Clinical Scorecard: The Evolving Glaucoma Toolbox

At a Glance

Key Highlights

• Incorporation of 10-2 visual field testing for earlier detection of central visual field loss, as emphasized by presenters.
• Selective laser trabeculoplasty (SLT) shown to be effective with long-term medication-free outcomes, supported by long-term data.
• Minimally invasive glaucoma surgery (MIGS) may reduce medication dependence and improve quality of life, based on evidence presented.
• Emerging drug-delivery technologies aim to enhance medication adherence, as discussed in the course.
• Consideration of systemic and vascular risk factors in normal-tension glaucoma management, as highlighted by the presenters.

Guideline-Based Recommendations

Diagnosis

• Utilize 10-2 visual field testing when central defects are suspected, as recommended by the presenters.

Management

• Consider SLT as a first-line treatment option or for patients with adherence challenges, as suggested by the presenters.

Monitoring & Follow-up

• Evaluate nocturnal IOP fluctuations and systemic risk factors in progressing NTG patients, as discussed in the course.

Risks

• Chronic glaucoma medications can lead to ocular surface issues affecting patient adherence, as noted by the presenters.

Patient & Prescribing Data

Patients with glaucoma, particularly those experiencing medication adherence issues.

Sustained-release and alternative drug-delivery platforms may improve treatment consistency.

Clinical Best Practices

• Assess ocular surface health and medication tolerance during consultations, as recommended by the presenters.
• Stay informed about emerging technologies in glaucoma management, as emphasized in the course.

Related Resources & Content

• Horizon trial data on Schlemm’s canal microstent